May 13, 2020 / 10:53 PM / 24 days ago

BRIEF-Merck Announces Data From Mid-Stage Kidney Cancer Trial Testing MK-6482

May 13 (Reuters) - Merck & Co Inc:

* MERCK’S NOVEL HIF-2Α INHIBITOR SHOWED AN OBJECTIVE RESPONSE RATE OF NEARLY 30% IN PATIENTS WITH VON HIPPEL-LINDAU (VHL) DISEASE-ASSOCIATED CLEAR CELL RENAL CELL CARCINOMA

* MERCK & CO INC - MK-6482 DEMONSTRATED DURABLE RESPONSES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below